{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:11:09Z","timestamp":1760746269867,"version":"build-2065373602"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Patients with mastocytosis have a higher risk of anaphylactic reactions. This study aims to assess the prevalence and risk factors of anaphylaxis among patients diagnosed with Systemic Mastocytosis (SM), including pre-diagnostic Systemic Mastocytosis (pre-SM), a subgroup of patients often overlooked in current classifications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective monocentric study was conducted at Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico in Milan, Italy. Patients aged \u226518 years diagnosed with SM or pre-SM between January 2009 and May 2025 were included. Demographic, clinical and laboratory data were analyzed using chi-squared test or Wilcoxon-Mann\u2013Whitney and Kruskal\u2013Wallis tests<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At the time of diagnosis, out of 162 patients (53% women), 29 (18%) experienced at least one episode of anaphylaxis. Hymenoptera venom was the main trigger (51.7%), followed by drugs (27.6%) and idiopathic cases (20.7%). Patients with anaphylaxis had 7% pre-SM, 48% BMM, 28% ISM, 0% SSM, 7% ASM, 10% SM-AHN, (<jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001). The prevalence of anaphylaxis in each subtype was as follows: 2\/12 (17%) in pre-SM, 14\/31 (45%) in BMM, 8\/97 (8%) in ISM, 0\/5 in SSM, 2\/4 (50%) in ASM and 3\/13 (23%) in SM-AHN, (<jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001). Hymenoptera venom\u2013induced anaphylaxis occurred exclusively in indolent forms (pre-SM, BMM, and ISM) while drug-induced anaphylaxis was observed in both ISM and advanced SM subtypes. Idiopathic anaphylaxis was more evenly distributed across all SM subtypes, (<jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001). The presence of cutaneous lesions was associated with a lower risk of anaphylaxis: 10\/114 (8.8%) vs. 19\/48 (39.6%) without skin involvement (<jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001), with a confirmed protective effect in both ISM and pre-SM. Male sex was identified as an additional risk factor, (<jats:italic>p<\/jats:italic>\u2009=\u20090.03). A history of Hymenoptera sting was associated with a higher risk of Hymenoptera venom anaphylaxis: 15\/113 (13%) vs. no reactions to the first sting in 47 patients, (<jats:italic>p<\/jats:italic>\u2009=\u20090.011).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Anaphylaxis is a relevant issue not only in acknowledged variants of SM, but also in pre-diagnostic forms. Idiopathic anaphylaxis may occur across different subtypes. Hymenoptera venom is the main trigger in indolent forms, whereas drug-induced reactions predominate in ISM and advanced SM, mainly through IgE-independent mechanisms. The risk of anaphylaxis is higher in pre-SM and ISM without cutaneous involvement, particularly in case of Hymenoptera venom sensitization. Our results highlight the need for allergological risk assessment and close monitoring especially in patients without skin lesions or with Hymenoptera venom sensitization.<\/jats:p><\/jats:sec>","DOI":"10.3389\/falgy.2025.1681051","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T05:30:01Z","timestamp":1760679001000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Pre-diagnostic and non-advanced systemic mastocytosis without cutaneous involvement have an increased risk of anaphylaxis"],"prefix":"10.3389","volume":"6","author":[{"given":"Andrea","family":"Sangalli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerio","family":"Pravettoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariarita","family":"Scium\u00e8","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dario","family":"Consonni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvio","family":"Sartorio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Montano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Rivolta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1146\/annurev-pathmechdis-031521-042618","article-title":"New insights into the pathogenesis of mastocytosis: emerging concepts in diagnosis and therapy","volume":"18","author":"Valent","year":"2023","journal-title":"Annu Rev Pathol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"B3","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.iac.2016.08.017","article-title":"Mastocytosis and anaphylaxis","volume":"37","author":"Schuch","year":"2017","journal-title":"Immunol Allergy Clin North Am"},{"key":"B4","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.iac.2023.04.011","article-title":"World health organization classification and diagnosis of mastocytosis: update 2023 and future perspectives","volume":"43","author":"Valent","year":"2023","journal-title":"Immunol Allergy Clin North Am"},{"key":"B5","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1080\/17843286.2022.2137631","article-title":"Mastocytosis and related entities: a practical roadmap","volume":"78","author":"Beyens","year":"2023","journal-title":"Acta Clin Belg"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1002\/ajh.26962","article-title":"Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management","volume":"98","author":"Pardanani","year":"2023","journal-title":"Am J Hematol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"5626","DOI":"10.3390\/cancers152356268","article-title":"Review and updates on systemic mastocytosis and related entities","volume":"15","author":"Li","year":"2023","journal-title":"Cancers"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e2021068","DOI":"10.4084\/MJHID.2021.068","article-title":"Systemic mastocytosis: multidisciplinary approach","volume":"13","author":"Zanotti","year":"2021","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.jaip.2017.02.008","article-title":"Risk factor analysis of anaphylactic reactions in patients with systemic mastocytosis","volume":"5","author":"G\u00fclen","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1111\/all.16084","article-title":"High burden of clonal mast cell disorders and hereditary \u03b1-tryptasemia in patients who need hymenoptera venom immunotherapy","volume":"79","author":"Koro\u0161ec","year":"2024","journal-title":"Allergy"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1111\/j.1365-2222.2007.02804.x","article-title":"Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA)","volume":"37","author":"Gonz\u00e1lez de Olano","year":"2007","journal-title":"Clin Exp Allergy"},{"key":"B12","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/cea.12225","article-title":"High prevalence of anaphylaxis in patients with systemic mastocytosis\u2014a single-centre experience","volume":"44","author":"G\u00fclen","year":"2014","journal-title":"Clin Exp Allergy"},{"key":"B13","doi-asserted-by":"publisher","first-page":"46","DOI":"10.20452\/pamw.2644","article-title":"Risk factors for anaphylaxis in patients with mastocytosis","volume":"125","author":"G\u00f3rska","year":"2015","journal-title":"Pol Arch Med Wewn"},{"key":"B14","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/j.1398-9995.2007.01569.x","article-title":"Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients","volume":"63","author":"Brockow","year":"2008","journal-title":"Allergy"},{"key":"B15","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.jaci.2013.06.020","article-title":"Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM","volume":"133","author":"Alvarez-Twose","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1097\/ACI.0000000000000567","article-title":"Mastocytosis presenting as insect anaphylaxis: gender differences and natural history","volume":"19","author":"Alvarez-Twose","year":"2019","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1182\/blood-2006-06-028100","article-title":"Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with \u201cidiopathic\u201d anaphylaxis","volume":"110","author":"Akin","year":"2007","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.jaip.2019.02.002","article-title":"Mast cell activation syndrome and mastocytosis: initial treatment options and long-term management","volume":"7","author":"Castells","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","first-page":"103043","DOI":"10.1016\/j.eclinm.2024.103043","article-title":"Characterization of patients with clonal mast cells in the bone marrow with clinical significance not otherwise specified","volume":"80","author":"Ballul","year":"2025","journal-title":"EClinicalMedicine"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e12132","DOI":"10.1002\/clt2.12132","article-title":"Mastocytosis presenting with mast cell-mediator release-associated symptoms elicited by cyclo oxygenase inhibitors: prevalence, clinical, and laboratory features","volume":"12","author":"Rama","year":"2022","journal-title":"Clin Transl Allergy"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.3390\/children9101473","article-title":"Hypersensitivity to intravenous iron preparations","volume":"9","author":"Caimmi","year":"2022","journal-title":"Children"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.1111\/all.16132","article-title":"Prevalence of hypersensitivity reactions in various forms of mastocytosis: a pilot study of 2485 adult patients with mastocytosis collected in the ECNM registry","volume":"79","author":"Niedoszytko","year":"2024","journal-title":"Allergy"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e3277","DOI":"10.1002\/hon.3277","article-title":"Comparison between indolent systemic mastocytosis and clonal mast cell disease not meeting WHO diagnostic criteria: a nationwide multicenter retrospective analysis","volume":"42","author":"Scium\u00e8","year":"2024","journal-title":"Hematol Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1038\/leu.2013.227","article-title":"Clonal mast cell disease not meeting WHO criteria for diagnosis of mastocytosis: clinicopathologic features and comparison with indolent mastocytosis","volume":"27","author":"Pardanani","year":"2013","journal-title":"Leukemia"},{"key":"B26","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/hon.2920","article-title":"Demystifying the diagnostic criteria of indolent systemic mastocytosis","volume":"40","author":"Grifoni","year":"2022","journal-title":"Hematol Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"6179","DOI":"10.1097\/MS9.0000000000002472","article-title":"Indolent systemic mastocytosis (ISM) without skin lesions as a recurrent anaphylaxis: a case report study","volume":"86","author":"Ghelichi-Ghojogh","year":"2024","journal-title":"Ann Med Surg"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2025.1681051\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T05:30:02Z","timestamp":1760679002000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2025.1681051\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":27,"alternative-id":["10.3389\/falgy.2025.1681051"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2025.1681051","relation":{},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"article-number":"1681051"}}